Academics and Research

A New Clinical Trial About Gastric Cancer was Reported in 2016 Gastrointestinal Cancers Symposium of ASCO


 

2016 Gastrointestinal (GI) Cancers Symposium of ASCO (American society of clinical oncology) was held on January 21-23 inSan Francisco, which was a specialized oncology event designed to provide scientific and educational content for members of the GI cancer care and research community. This three-day meeting encompassed the latest progress in colorectal cancer, stomach cancer, liver cancer, esophageal cancer. The topic of ASCO-GI 2016 is "Insight on Novel Mechanisms and Precision Care".


After evaluation by the Academic Committee of ASCO-GI, Bi Feng (MD, PhD, Director of Department of Abdominal Oncology, West China Hospital, Sichuan University) was invited to give an oral presentation, titled “Prospective randomized phase II study of FOLFIRI versus FOLFOX7 inadvanced gastric adenocarcinoma: A Chinese Western Cooperative Gastrointestinal Oncology Group study”, finished by Western Cooperative Gastrointestinal Oncology Group and leaded by Dr. Bi Feng. This study was started in 2007, and the purpose was to compare mFOLFIRI (arm A) with mFOLFOX7 (arm B) as first-line treatments in patients with locally advanced gastric adenocarcinoma in an open, randomized, phase II study. The second-line treatment was mFOLFOX7 for arm A and mFOLFIRI for arm B. In total,200 ptswere included. The evaluable population consisted of128 pts(54 inarm A;74 inarm B). The median PFS of arm A was 2.9 months (1.9 to4.1 m) versus4.1 m(3.2 to4.8 m) for arm B (p=0.109). The median OS was 9.9 months (6.0 to13.5 m) for arm A versus12.0 mfor arm B (10.3 to13.7m; p= 0.431). There was no significant difference in the PFS or DCR. However, mFOLFOX7 followed by mFOLFIRI might have a better OS. Clinical trial information: ChiCTR-TRC-08000167.

This work was highly appreciated by the Chairmen of the symposium. This is also an outcome of collabortion which West China Hospital, Sichuan University provided over 70% cases. Dr. Bi Feng, PI of this clinical trial, is the only one who was invited to give the oral presentation in the symposium fromChina.